clinical trial · NCT06088290
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
PharmaMar·phase3·recruiting·n = 450
LeiomyosarcomaLurbinectedinDoxorubicin
brief summary
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
started
Sep 21, 2023
primary completion
Aug 30, 2029
completion
Aug 30, 2029
last updated
Apr 17, 2026
official title
Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol